Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy
- PMID: 18937663
- DOI: 10.1111/j.1365-4632.2008.03724.x
Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy
Abstract
Pegylated interferon-alpha in combination with ribavirin currently represents the therapeutic standard for the hepatitis C virus infection. Interferon based therapy may be responsible for many cutaneous side effects. We report a case of drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy. To our knowledge, this is the first reported case of Sweet's syndrome in association with pegylated interferon-alpha therapy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
